GSK’s investigational liver therapy, efimosfermin, receives US FDA Breakthrough Therapy and EMA Prio

GSK’s investigational liver therapy, efimosfermin, receives US FDA Breakthrough Therapy and EMA Priority Medicines (PRIME) designations for MASH

Designations recognise potential for efimosfermin to address significant unmet medical need & reflect momentum in GSKs liver health pipeline